Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial - Kadowaki, T; Isendahl, J; Khalid, U (The Lancet Diabetes & Endocrinology, 2022)
et al.